A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Now used for type 2 diabetes, new study shows GLP-1 drugs helped people with type 1 keep blood glucose levels in a healthy range while also losing weight.

EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Many of the GLP-1 patients in their study also never reached the maximum dose. Chhabra also suspects that many people in the real world aren’t getting the supportive care and follow-up they ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Sai Lomte, Tarun. (2025, May 14). GLP-1 weight loss drugs leave users low on key nutrients, study ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

WASHINGTON, DC – June 17, 2025 – Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or ...

About 12% of Americans say they have ever taken a GLP-1 drug, ... Head-to-head study shows bariatric surgery superior to GLP-1 drugs for weight loss (2025, June 17) ...